WEKO3
アイテム
Preclinical study of alpha-radioimmunotherapy against HER2+ liver metastasis of gastric cancer
https://repo.qst.go.jp/records/72757
https://repo.qst.go.jp/records/7275732f8add7-ea85-48aa-9a92-c3cb3ef6595d
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2018-04-27 | |||||
| タイトル | ||||||
| タイトル | Preclinical study of alpha-radioimmunotherapy against HER2+ liver metastasis of gastric cancer | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
李, 惠子
× 李, 惠子× 長谷川, 純崇× 李 惠子× 長谷川 純崇 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Background / Aims: Gastric cancer (GC) is one of the main causes of cancer-related death. Almost 1/3 of GC patients has distant metastasis at the time of diagnosis. Liver metastasis (LM) is one of the common metastatic pattern of GC, which is classified as STAGE 4. Unfortunately, the therapeutic efficacy of current standard treatments for LMGC are still limited and the five years survival is less than 10%. It has been reported that about 70% of LMGC are HER2-positive (HER2+), so HER2 can be an attractive therapeutic target. Alpha-radioimmunotherapy (alpha-RIT) is getting higher attention with the advantage of the combination of cancer specific targeting of antibodies and high cell killing effect of alpha-particle. Astatine-211 (211At) is one of the promising alphaemitter, which has appropriate half-life (7.2 h) and 100% emit alpha-particle during its decay. The aim of this study is to evaluate the therapeutic efficacy of alpha-RIT against HER2+ LMGC using 211At-labeled anti-HER2 antibody, trastuzumab (211At-trastuzumab). Methods: A LMGC mouse model was established by transplanting luciferase-labeled NCl-N87, HER2+ human GC cell, to mice from splenic vein. 211At was labeled to trastuzumab by tin-halogen exchange. Biodistribution study was performed to evaluate the tumor accumulation of 211At-trastuzumab. Experimental therapy was performed by injecting 211At-trastuzumab (1 MBq) to LMGC mice from tail vein. The tumor were monitored by luminescence imaging and body weight and the number of white blood cells were monitored to check the toxicity. Results: Tumor accumulation of 211At-trastuzumab were increased along with the time and reached about 12% at 24 h post injection. 211At-trastuzumab effectively eradicated the LMGC in our mouse model while the tumor in the control group were aggressively grown. Conclusion: Alpha-RIT using 211At-trastuzumab could be a novel therapeutic option for HER2+ LMGC. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 12th Congress of the world federation of nuclear medicine and biology | |||||
| 発表年月日 | ||||||
| 日付 | 2018-04-22 | |||||
| 日付タイプ | Issued | |||||
